Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN FRANCISCO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC.(OLEMA, OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUALEVERCORE HEALTHCARE CONFERENCE ONWEDNESDAY, DECEMBER 3, 2025 AT 12:55 P.M. ET. LIVE WEBCASTS AND RECORDINGS OF THESE PRESENTATIONS WILL BE AVAILABLE, AS PERMITTED BY THE EVENT HOST, IN THE EVENTS AND PRESENTATIONS SECTION OF OLEMA'S INVESTOR RELATIONS WEBSITE AT IR.OLEMA.COM.

OLEMA ONCOLOGY TO PARTICIPATE IN 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

OLEMA ONCOLOGY ANNOUNCES CLOSING OF $218.5 MILLION PUBLIC OFFERING OF COMMON STOCK AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SAN FRANCISCO, NOV. 18, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED ITS PLANS TO COMMENCE A PUBLIC OFFERING, SUBJECT TO MARKET AND OTHER CONDITIONS, TO ISSUE AND SELL SHARES OF ITS COMMON STOCK, OR FOR CERTAIN INVESTORS THAT SO CHOOSE, IN LIEU OF SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL OF THE SECURITIES ARE BEING OFFERED BY OLEMA.

OLEMA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

ANNOUNCED NEW CLINICAL TRIAL AGREEMENT WITH PFIZER TO EVALUATE PALAZESTRANT IN COMBINATION WITH ATIRMOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER INITIATED OPERA-02 PHASE 3 TRIAL OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN FRONTLINE ER+/HER2- METASTATIC BREAST CANCER PRESENTED COMPELLING NEW DATA FROM PHASE 1B/2 STUDY OF PALAZESTRANT PLUS RIBOCICLIB AT ESMO 2025 ENDED THE QUARTER WITH $329.0 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES SAN FRANCISCO, NOV. 10, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. "WE HAVE MADE SIGNIFICANT PROGRESS ADVANCING OUR PROGRAMS THIS QUARTER, HIGHLIGHTED BY THE INITIATION OF THE PHASE 3 OPERA-02 TRIAL EVALUATING PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN THE FRONTLINE SETTING AND THE PRESENTATION OF COMPELLING DATA AT ESMO THAT FURTHER POSITIONS PALAZESTRANT TO BECOME A POTENTIAL BEST-IN-CLASS BACKBONE ENDOCRINE THERAPY FOR ER+/HER2- METASTATIC BREAST CANCER, SAID SEAN P.

OLEMA ONCOLOGY REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

SAN FRANCISCO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FIVE NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 148,600 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF NOVEMBER 3, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN FRANCISCO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC.(OLEMA, OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: GUGGENHEIM 2 ND ANNUAL HEALTHCARE INNOVATION CONFERENCE DATE AND TIME: NOVEMBER 10, 2025 AT 10:30 A.M. ET FORMAT: FIRESIDE CHATLOCATION: BOSTON, MA UBS GLOBAL HEALTHCARE CONFERENCE 2025 DATE AND TIME: NOVEMBER 12, 2025 AT 8:00 A.M.

OLEMA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN FRANCISCO, OCT. 30, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC.(OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED IT WILL PRESENT A TRIAL-IN-PROGRESS POSTER FOR THE PHASE 3 OPERA-02 TRIAL AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS 2025) TAKING PLACE DECEMBER 9-12, 2025 IN SAN ANTONIO, TX. THE TRIAL IS EVALUATING PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN FRONTLINE ESTROGEN RECEPTOR-POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER.

OLEMA ONCOLOGY TO PRESENT TRIAL-IN-PROGRESS POSTER FOR PHASE 3 OPERA-02 TRIAL OF PALAZESTRANT PLUS RIBOCICLIB AT SABCS 2025

PALAZESTRANT IN COMBINATION WITH RIBOCICLIB DEMONSTRATED ENCOURAGING ACTIVITY ACROSS ALL DOSE COHORTS AND SUBGROUPS MEDIAN PFS WAS 15.5 MONTHS IN THE 120 MG PALAZESTRANT COHORT ACROSS ALL PATIENTS IN THE 120 MG PALAZESTRANT COHORT AMONG PATIENTS WITH PRIOR CDK4/6I TREATMENT, MEDIAN PFS WAS 9.2 MONTHS IN PATIENTS WITH ESR1 WILD-TYPE TUMORS AND 13.8 MONTHS IN PATIENTS WITH ESR1 MUTANT TUMORS COMBINATION CONTINUES TO DEMONSTRATE FAVORABLE TOLERABILITY AND A SAFETY PROFILE CONSISTENT WITH THE KNOWN PROFILES OF EACH DRUG DATA SUPPORT THE ONGOING PHASE 3 OPERA-02 TRIAL OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN FRONTLINE ADVANCED OR METASTATIC BREAST CANCER SAN FRANCISCO, OCT. 18, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED UPDATED DATA FROM THE PHASE 1B/2 STUDY OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER. THESE FINDINGS WILL BE PRESENTED IN A POSTER SESSION ON OCTOBER 20 AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025 IN BERLIN, GERMANY.

OLEMA ONCOLOGY ANNOUNCES NEW DATA FROM THE PHASE 1B/2 TRIAL OF PALAZESTRANT PLUS RIBOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER AT ESMO 2025

SAN FRANCISCO, OCT. 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO THREE NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 77,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF OCTOBER 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 124,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF SEPTEMBER 2, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Olema Pharmaceuticals, Inc.

OLMA

Price

Financial Reports

No items found.

Press Releases

Olema Pharmaceuticals, Inc.

OLMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OLMA